Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 3
2015 8
2016 10
2017 14
2018 14
2019 22
2020 15
2021 8
2022 9
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scheen AJ. Scheen AJ. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1303-1316. doi: 10.1080/17512433.2017.1389645. Epub 2017 Oct 18. Expert Rev Clin Pharmacol. 2017. PMID: 28984487 Review.
Saxagliptin (a dipeptidyl peptidase-4 inhibitor, DPP-4i) and dapagliflozin (a sodium-glucose cotransporter type 2 inhibitor, SGLT2i) improve glucose control in type 2 diabetes (T2D) through different potentially complementary mechanisms, thus offering the opportunit …
Saxagliptin (a dipeptidyl peptidase-4 inhibitor, DPP-4i) and dapagliflozin (a sodium-glucose cotransporter type 2 inhibitor, S …
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
Williams DM, Stephens JW. Williams DM, et al. Expert Opin Pharmacother. 2015;16(15):2373-9. doi: 10.1517/14656566.2015.1088830. Expert Opin Pharmacother. 2015. PMID: 26389773 Review.
AREAS COVERED: This review examines the current available literature on the combination of saxagliptin and dapagliflozin as a treatment option, which is likely to be available as a fixed-dose combination in 2016. ...EXPERT OPINION: To date, the limited literature su …
AREAS COVERED: This review examines the current available literature on the combination of saxagliptin and dapagliflozin as a …
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
Coppenrath VA, Hydery T. Coppenrath VA, et al. Ann Pharmacother. 2018 Jan;52(1):78-85. doi: 10.1177/1060028017731111. Epub 2017 Sep 8. Ann Pharmacother. 2018. PMID: 28884600 Review.
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablets. DATA SOURCES: Searches of MEDLINE (1946 to July 1, 2017) were conducted using the …
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, …
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Koshino A, Neuen BL, Jongs N, Pollock C, Greasley PJ, Andersson EM, Hammarstedt A, Karlsson C, Langkilde AM, Wada T, Heerspink HJL. Koshino A, et al. Cardiovasc Diabetol. 2023 Nov 28;22(1):330. doi: 10.1186/s12933-023-02027-8. Cardiovasc Diabetol. 2023. PMID: 38017482 Free PMC article. Clinical Trial.
BACKGROUND: This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation. METHODS: Patients with type 2 diabetes and albuminuria were randomized to dapagliflozin, dapagliflozin …
BACKGROUND: This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and …
Co-delivery of saxagliptin and dapagliflozin by electrosprayed trilayer poly ((D,)(l)-lactide-co-glycolide) nanoparticles for controlled drug delivery.
Zhang Y, Henry Harker A, Luo CJ, Parhizkar M, Edirisinghe M. Zhang Y, et al. Int J Pharm. 2022 Nov 25;628:122279. doi: 10.1016/j.ijpharm.2022.122279. Epub 2022 Oct 13. Int J Pharm. 2022. PMID: 36243324
In this study, a single-step coaxial electrospray technique is presented that achieves over 90 % co-encapsulation of the saxagliptin and dapagliflozin, two drugs treating type 2 diabetes, into biodegradable poly ((d)(,)(l)-lactide-co-glicolide) (PLGA) nanoparticles. …
In this study, a single-step coaxial electrospray technique is presented that achieves over 90 % co-encapsulation of the saxagliptin …
Univariate and Multivariate Determination of Dapagliflozin and Saxagliptin in Bulk and Dosage Form.
Elhassan MM, Mahmoud AM, Hegazy MA, Mowaka S. Elhassan MM, et al. J AOAC Int. 2023 May 3;106(3):794-803. doi: 10.1093/jaoacint/qsac143. J AOAC Int. 2023. PMID: 36355446
BACKGROUND: Dapagliflozin is a sodium glucose cotransporter-II inhibitor while saxagliptin is a dipeptidyl peptidase-4 inhibitor. ...CONCLUSION: Four accurate, specific, and precise UV-spectrophotometric methods for dapagliflozin and saxagliptin testin …
BACKGROUND: Dapagliflozin is a sodium glucose cotransporter-II inhibitor while saxagliptin is a dipeptidyl peptidase-4 inhibit …
Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.
Yu H, Woo VC. Yu H, et al. Diabetes Metab Syndr Obes. 2017 Jul 21;10:317-332. doi: 10.2147/DMSO.S117982. eCollection 2017. Diabetes Metab Syndr Obes. 2017. PMID: 28769579 Free PMC article. Review.
AIMS: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the management of patients with type 2 diabetes. ...CONCLUSION: Dapagliflozin/saxagliptin combination is generally well tole …
AIMS: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination i …
Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2017 Mar;77(3):319-330. doi: 10.1007/s40265-017-0697-1. Drugs. 2017. PMID: 28176222 Review.
Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern()) are indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus (T2DM), either when treatment with metformin and/or a sulfonylurea plus a monocomponent of …
Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern()) are indicated in the EU for the improvement of glycaemic co …
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ. Scheen AJ. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588. Circ Res. 2018. PMID: 29748368 Free PMC article. Review.
An unexpected higher risk of hospitalization for heart failure was reported with saxagliptin. SGLT-2 inhibitors (gliflozins) promote glucosuria, thus reducing glucose toxicity and body weight, and enhance natriuresis, thus lowering blood pressure. ...Ongoing CV outcome tri …
An unexpected higher risk of hospitalization for heart failure was reported with saxagliptin. SGLT-2 inhibitors (gliflozins) promote …
105 results